European Psychiatry (Jun 2022)

Pregabalin for the treatment of generalized anxiety disorder

  • A. Khallouk,
  • A. Rhaouti,
  • A. Boukdir,
  • S. Stati,
  • H. Nafiaa,
  • A. Ouanass

DOI
https://doi.org/10.1192/j.eurpsy.2022.1011
Journal volume & issue
Vol. 65
pp. S399 – S399

Abstract

Read online

Introduction Pregabalin is a treatement with a complexe mechanism of action. It’s an antiepileptic drug used as adjunctive treatment of partial epilepsy, it is also taken in the treatment of neuropathic pain, and generalized anxiety disorder, in addition to epilepsy. Some of the advantages of pregabalin include. pharmacokinetics, safety, and tolerability. Clinical trials have demonstrated the efficacy of pregabalin comparable to benzodiazepines, without risk of abuse. Objectives to assess the efficacy of pregabalin in patients with generalized anxiety disorder in the Ar-Razi university psychiatric hospital in Salé in Morocco Methods To assess the place of pregabalin in the treatement of anxiety disorders through patients hospitalized in the Ar-Razi university psychiatric hospital in Salé in Morocco The evaluation instruments are: For anxiety the Hamilton Anxiety Scale and For therapeutic efficacy CGI-therapeutic index Results based on the results of our study on the patients who have improved after an optimal duration of treatment, in conjunction with psychological monitoring, we retain that pregabalin can significantly improve the quality of life of anxious patients and also guarantee them a better prognosis Conclusions Pregabalin was significantly more efficacious for the treatment of psychic and somatic symptoms of generalized anxiety disorder and was well tolerated by most study patients. Disclosure No significant relationships.

Keywords